Garcia VC, Mansfield C, Leach C, Pierce A, Smith JC, Afonso M. Patient and caregiver preferences for hemophilia treatments: a discrete-choice experiment. Haemophilia. 2024 Mar;30(2):375-87. doi: 10.1111/hae.14928
Earnshaw SR, Graham CN, McDade CL, Spears JB, Kessler CM. Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment. Haemophilia. 2015 May;21(3):310-9. doi: 10.1111/hae.12621
Kruse-Jarres R, Gilsenan AW, Spears J, Kaye JA. Prospective, observational study of plasma-derived factor VIII/von Willebrand factor in immune tolerance induction: the PRISM registry. Haemophilia. 2015 Mar;21(2):e122-4. doi: 10.1111/hae.12590
DiBenedetti DB, Coles TM, Sharma T, Pericleous L, Kulkarni R. Assessing patients' and caregivers' perspectives on stability of factor VIII products for haemophilia A: a web-based study in the United States and Canada. Haemophilia. 2014 Jul;20(4):e296-303. doi: 10.1111/hae.12459
Brown TM, Pashos CL, Joshi AV, Lee WC. The perspective of patients with haemophilia with inhibitors and their care givers: preferences for treatment characteristics. Haemophilia. 2011 May 1;17(3):476-82.
Knight C, Plun-Favreau J, Johal S. An economic model to evaluate the cost-effectiveness of prophylaxis regimens on haemophilia patients with inhibitors. Poster presented at the XXIXth International Congress of the World Federation of Hemophilia; July 2010. Buenos Aires, Argentina. [abstract] Haemophilia. 2010 Jun; 16(Suppl 4):127.
Brown TM, Lee WC, Joshi AV, Pashos CL. Health-related quality of life and productivity impact in haemophilia patients with inhibitors. Haemophilia. 2009 Jul 1;15(4):911-7.
Knight C, Dano AM, Kennedy-Martin T. A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors. Haemophilia. 2009 Mar 1;15(2):405-19.
Lee WC, Joshi AV, Woolford S, Sumner M, Brown TM, Hadker N, Pashos CL. Physicians' preferences towards coagulation factor concentrates in the treatment of haemophilia with inhibitors: a discrete choice experiment. Haemophilia. 2008 May 1;3(14):454-65.
Knight CJ. Health economics of treating hemophilia A with inhibitors. Haemophilia. 2005 Nov 1;11:11-7.
Knight C. Health economics of treating haemophilia a with inhibitors. Haemophilia. 2005 Nov;11(Suppl 1):11-7.
DiBenedetti DB, Gondek K, Sagnier PP, Kubin M, Keininger D, Marquis P. The treatment satisfaction scale: a multidimensional instrument for the assessment of treatment satisfaction for erectile dysfunction patients and their partners. Eur Urol. 2005 Sep 1;48(3):503-11.
Wight J, Paisley S, Knight C. Immune tolerance induction in patients with haemophilia a with inhibitors: a systematic review. Haemophilia. 2003 Jul;9(4):436-63.
Knight C, Paisley S, Wight J, Jones ML. Economic modelling of different treatment strategies for haemophilia a with high-responding inhibitors. Poster presented at the World Federation of Hemophilia Congress; June 2002. Seville, Spain. [abstract] Haemophilia. 2003 Jul; 9(4):521-40.
Paisley S, Wight J, Currie E, Knight CJ. The management of inhibitors in haemophilia a: introduction and systematic review of current practice. Haemophilia. 2003 Jul;9(4):405-17.
Lloyd Jones M, Wight J, Paisley S, Knight C. Control of bleeding in patients with haemophilia a with inhibitors: a systematic review. Haemophilia. 2003 Jul;9(4):464-520.
Overland GB, Vatten L, Rhodes T, DeMuro C, Jacobsen G, Vada K, Angelsen A, Girman CJ. Lower urinary tract symptoms, prostate volume and uroflow in Norwegian community men. Eur Urol. 2001 Jan 1;39(1):36-41.